Feverfew: Weeding out the root of leukaemia

Expert Opinion on Biological Therapy

Volumn 5, Issue 9, 2005, Pages 1147-1152

  Guzman, Monica L ^a   Jordan, Craig T ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Acute myelogenous leukaemia; AML; Cancer; Chemotherapy; Feverfew; Medicinal plant; NF kappaB; Parthenolide; Sesquiterpene lactone; Stem cells

Indexed keywords

3 NITROTYROSINE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTHRACYCLINE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CYTARABINE; DOCETAXEL; I KAPPA B KINASE; IDARUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; MAGNESIUM; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NITRIC OXIDE; PACLITAXEL; PARTHENOLIDE; PROTEIN P53; REACTIVE OXYGEN METABOLITE; RECOMBINANT PROTEIN; RIBOFLAVIN; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; SULINDAC; TAMOXIFEN; TANACETUM PARTHENIUM EXTRACT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ASTHMA; CARDIOTOXICITY; CHEMOSENSITIVITY; CLINICAL TRIAL; DRUG MECHANISM; HUMAN; HYPERALGESIA; HYPOTENSION; INFLAMMATION; LEISHMANIASIS; MIGRAINE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PAPILLOMA; PATHOGENESIS; PREMENSTRUAL SYNDROME; RASH; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SEPTIC SHOCK; STOMACH PAIN; SURVIVAL RATE; TANACETUM PARTHENIUM; TOOTH PAIN; TREATMENT OUTCOME; VASODILATATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL LINE, TUMOR; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; NF-KAPPA B; PLANTS, MEDICINAL; SESQUITERPENES; TANACETUM PARTHENIUM; TUMOR STEM CELLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

TANACETUM PARTHENIUM;

EID: 24144443802     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.5.9.1147     Document Type: Review

References (47)

1. FIALKOW PJ, JACOBSON RJ, PAPAYANNOPOULOU T: Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am. J. Med. (1977) 63:125-130.
2. BONNET D, DICK JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. (1997) 3:730-737.
3. BLAIR A, HOGGE DE, SUTHERLAND HJ: Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34(+)/CD71(-)/HLA-DR. Blood (1998) 92:4325-4335.
4. LAPIDOT T, SIRARD C, VORMOOR J et al.: A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature (1994) 367:645-648.
5. GUAN Y, GERHARD B, HOGGE DE: Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood (2003) 101:3142-3149.
6. GUZMAN ML, NEERING SJ, UPCHURCH D et al.: Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood (2001) 98:2301-2307.
7. HOLYOAKE T, JIANG X, EAVES C, EAVES A: Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood (1999) 94:2056-2064.
8. COX CV, EVELY RS, OAKHILL A, PAMPHILON DH, GOULDEN NJ, BLAIR A: Characterization of acute lymphoblastic leukemia progenitor cells. Blood (2004) 104:2919-2925.
9. WANG JC, LAPIDOT T, CASHMAN JD et al.: High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase. Blood (1998) 91:2406-2414.
10. MAYO MW, BALDWIN AS: The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance. Biochim. Biophys. Acta (2000) 1470:M55-M62.
11. BALDWIN AS: Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin. Invest. (2001) 107:241-246.
12. BARGOU RC, EMMERICH F, KRAPPMANN D et al.: Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J. Clin. Invest. (1997) 100:2961-2969.
13. SWEENEY C, LI L, SHANMUGAM R et al.: Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin. Cancer Res. (2004) 10:5501-5507.
14. NAKSHATRI H, BHAT-NAKSHATRI P, MARTIN DA, GOULET RJ, SLEDGE GW: Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol. Cell. Biol. (1997) 17:3629-3639.
15. KIM JY, LEE S, HWANGBO B et al.: NF-kappaB activation is related to the resistance of lung cancer cells to TNF-alpha-induced apoptosis. Biochem. Biophys. Res. Commun. (2000) 273:140-146.
16. GUZMAN ML, SWIDERSKI CF, HOWARD DS et al.: Preferential induction of apoptosis for primary human leukemic stem cells. Proc. Natl. Acad. Sci. USA (2002) 99:16220-16225.
17. OBERLIES NH, KROLL DJ: Camptothecin and taxol: historic achievements in natural products research. J. Nat. Prod. (2004) 67:129-135.
18. WOODROW CJ, HAYNES RK, KRISHNA S: Artemisinins. Postgrad. Med. J. (2005) 81:71-78.
19. RATES SM: Plants as source of drugs. Toxicon (2001) 39:603-613.
20. HEINRICH M: Ethnobotany and its role in drug development. Phytother. Res. (2000) 14:479-488.
21. HEHNER SP, HOFMANN TG, DROGE W, SCHMITZ ML: The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-kappa B by targeting the I kappa B kinase complex. J. Immunol. (1999) 163:5617-5623.
22. KWOK BH, KOH B, NDUBUISI MI, ELOFSSON M, CREWS CM: The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. Chem. Biol. (2001) 8:759-766.
23. GARCIA-PINERES AJ, CASTRO V, MORA G et al.: Cysteine 38 in p65/NF-kappaB plays a crucial role in DNA binding inhibition by sesquiterpene lactones. J. Biol. Chem. (2001) 276:39713-39720.
24. GARCIA-PINERES AJ, LINDENMEYER MT, MERFORT I: Role of cysteine residues of p65/NF-kappaB on the inhibition by the sesquiterpene lactone parthenolide and N-ethyl maleimide, and on its transactivating potential. Life Sci. (2004) 75:841-856.
25. ZHANG S, ONG CN, SHEN HM: Critical roles of intracellular thiols and calcium in parthenolide-induced apoptosis in human colorectal cancer cells. Cancer Lett. (2004) 208:143-153.
26. MIGLIETTA A, BOZZO F, GABRIEL L, BOCCA C: Microtubule-interfering activity of parthenolide. Chem. Biol. Interact. (2004) 149:165-173.
27. WEN J, YOU KR, LEE SY, SONG CH, KIM DG: Oxidative stress-mediated apoptosis. The anticancer effect of the sesquiterpene lactone parthenolide. J. Biol. Chem. (2002) 277:38954-38964.
28. SOBOTA R, SZWED M, KASZA A, BUGNO M, KORDULA T: Parthenolide inhibits activation of signal transducers and activators of transcription (STATs) induced by cytokines of the IL-6 family. Biochem. Biophys. Res. Commun. (2000) 267:329-333.
29. ZHANG S, LIN ZN, YANG CF, SHI X, ONG CN, SHEN HM: Suppressed NF-{kappa}B and sustained JNK activation contribute to the sensitization effect of parthenolide to TNF-{alpha}-induced apoptosis in human cancer cells. Carcinogenesis (2004) 25(11):2191-2199.
30. MAIZELS M, BLUMENFELD A, BURCHETTE R: A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial. Headache (2004) 44:885-890.
31. ERNST E, PITTLER MH: The efficacy and safety of feverfew (Tanacetum parthenium L.): an update of a systematic review. Public Health Nutr. (2000) 3:509-514.
32. TIUMAN TS, UEDA-NAKAMURA T, GARCIA CORTEZ DA et al.: Antileishmanial activity of parthenolide, a sesquiterpene lactone isolated from Tanacetum parthenium. Antimicrob. Agents Chemother. (2005) 49:176-182.
33. WIEDHOPF RM, YOUNG M, BIANCHI E, COLE JR: Tumor inhibitory agent from Magnolia grandiflora (Magnoliaceae). I. Parthenolide. J. Pharm. Sci. (1973) 62:345.
34. WON YK, ONG CN, SHIX, SHEN HM: Chemopreventive activity of parthenolide against UVB-induced skin cancer and its mechanisms. Carcinogenesis (2004) 25:1449-1458.
35. PATEL NM, NOZAKI S, SHORTLE NH et al.: Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide. Oncogene (2000) 19:4159-4169.
36. NAKSHATRI H, RICE SE, BHAT-NAKSHATRI P: Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase. Oncogene (2004) 23(44):7330-7344.
37. DEGRAFFENRIED LA, CHANDRASEKAR B, FRIEDRICHS WE et al.: NF-kappa B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen. Ann. Oncol. (2004) 15:885-890.
38. SWEENEY CJ, MEHROTRA S, SADARIA MR et al.: The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer. Mol. Cancer Ther. (2005) 4:1004-1012.
39. YIP-SCHNEIDER MT, NAKSHATRI H, SWEENEY CJ, MARSHALL MS, WIEBKE EA, SCHMIDT CM: Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells. Mol. Cancer Ther. (2005) 4:587-594.
40. GUZMAN ML, ROSSI RM, KARNISCHKY L et al.: The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood (2005) 105:4163-4169.
41. CURRY EA 3RD, MURRY DJ, YODER C et al.: Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer. Invest. New Drugs (2004) 22:299-305.
42. SIEDLE B, GARCIA-PINERES AJ, MURILLO R et al.: Quantitative structure-activity relationship of sesquiterpene lactones as inhibitors of the transcription factor NF-kappaB. J. Med. Chem. (2004) 47:6042-6054.
43. LI-WEBER M, PALFI K, GIAISI M, KRAMMER PH: Dual role of the anti-inflammatory sesquiterpene lactone: regulation of life and death by parthenolide. Cell Death Differ. (2005) 12:408-409.
44. POZAROWSKI P, HALICKA DH, DARZYNKIEWICZ Z: Cell cycle effects and caspase-dependent and independent death of HL-60 and Jurkat cells treated with the inhibitor of NF-kappaB parthenolide. Cell Cycle (2003) 2:377-383.
45. FELTENSTEIN MW, SCHUHLY W, WARNICK JE, FISCHER NH, SUFKA KJ: Anti-inflammatory and anti-hyperalgesic effects of sesquiterpene lactones from Magnolia and Bear's foot. Pharmacol. Biochem. Behav. (2004) 79:299-302.
46. SHEEHAN M, WONG HR, HAKE PW, MALHOTRA V, O'CONNOR M, ZINGARELLI B: Parthenolide, an inhibitor of the nuclear factor-kappaB pathway, ameliorates cardiovascular derangement and outcome in endotoxic shock in rodents. Mol. Pharmacol. (2002) 61:953-963.
47. SHEEHAN M, WONG HR, HAKE PW, ZINGARELLI B: Parthenolide improves systemic hemodynamics and decreases tissue leukosequestration in rats with polymicrobial sepsis. Crit. Care Med. (2003) 31:2263-2270.